Repligen (NASDAQ:RGEN) Stock Unloaded Rep. Lisa C. McClain

Posted by Casey Walker on Nov 28th, 2025

Representative Lisa C. McClain (R-Michigan) recently sold shares of Repligen Corporation (NASDAQ:RGEN). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Repligen stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Repligen Stock Performance

Shares of NASDAQ:RGEN traded down $0.58 during trading on Thursday, hitting $171.18. 498,847 shares of the stock were exchanged, compared to its average volume of 823,434. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The company has a market capitalization of $9.64 billion, a price-to-earnings ratio of 8,563.28, a price-to-earnings-growth ratio of 3.32 and a beta of 1.15. The company’s fifty day simple moving average is $148.75 and its 200-day simple moving average is $131.51. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59.

Repligen (NASDAQ:RGEN – Get Free Report) last issued its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. The business had revenue of $188.81 million during the quarter, compared to analyst estimates of $181.23 million. Repligen had a return on equity of 4.70% and a net margin of 0.25%.Repligen’s revenue was up 21.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.43 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Sell-side analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Evercore ISI upped their target price on shares of Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Canaccord Genuity Group raised their price target on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research note on Wednesday, October 29th. Hsbc Global Res raised Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. Finally, Jefferies Financial Group set a $160.00 price objective on Repligen and gave the company a “hold” rating in a research note on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $173.85.

View Our Latest Research Report on RGEN

Insider Activity at Repligen

In other news, COO James Bylund sold 2,191 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the transaction, the chief operating officer owned 21,520 shares of the company’s stock, valued at $3,254,039.20. This represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Anthony Hunt sold 25,000 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $156.88, for a total value of $3,922,000.00. Following the completion of the transaction, the director owned 100,743 shares in the company, valued at $15,804,561.84. This represents a 19.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 49,382 shares of company stock worth $7,676,802 over the last 90 days. 1.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Repligen

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC boosted its holdings in Repligen by 1.9% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock valued at $584,000 after acquiring an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in Repligen by 1.0% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company’s stock valued at $961,000 after purchasing an additional 80 shares during the period. Alliance Wealth Advisors LLC UT boosted its stake in shares of Repligen by 2.5% in the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 89 shares during the last quarter. Drive Wealth Management LLC grew its position in shares of Repligen by 2.5% during the 2nd quarter. Drive Wealth Management LLC now owns 3,796 shares of the biotechnology company’s stock worth $472,000 after buying an additional 93 shares during the period. Finally, Hilltop National Bank raised its stake in shares of Repligen by 8.0% during the third quarter. Hilltop National Bank now owns 1,276 shares of the biotechnology company’s stock worth $171,000 after buying an additional 95 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Repligen Company Profile

(Get Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.